Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Molecular Diagnostics: Page 3
Bio-Rad Laboratories Q1 net sales drop 3%; firm lowers full-year guidance
Bio-Rad shares were down on Friday, a day after the firm updated its financial outlook for full-year 2023; it anticipates non-GAAP currency-neutral revenue growth of approximately 4.5% compared to its previous estimate of 6% to 7%.
May 5, 2023
Qiagen Q1 net sales decline 23% on COVID headwinds; non-COVID sales rise
Non-COVID product group sales rose due to underlying double-digit growth at constant exchange rates in consumables and related revenues.
May 4, 2023
UC San Francisco becomes first California hospital to offer pharmacogenetic testing
When a patient agrees to undergo pharmacogenetic testing, UC San Francisco will bill their insurance and post the results in its portal within two weeks.
May 4, 2023
Bio-Techne fiscal Q3 sales rise 1% on strength in cell therapy, prostate test products
Among recent business highlights, the firm noted its ExoDx Prostate test increased its addressable market by approximately 50% after receiving expanded Medicare coverage.
May 3, 2023
PacBio Q1 revenue rises 17%
The company received its first orders for the Onso short-read sequencing system and released new workflows in collaboration with Corteva Agriscience that enable the sequencing of thousands of plant and microbial genome samples annually.
May 2, 2023
QuidelOrtho Q1 revenues drop with lower respiratory testing
On a supplemental combined basis, first-quarter respiratory testing revenues, including COVID-19 testing, fell 72% year-over-year to $265.6 million from $947.3 million. Non-respiratory testing revenues rose 5% year-over-year.
May 3, 2023
Illumina, Icahn issue letters to sequencing firm's shareholders, escalating proxy battle
Citing dissatisfaction with the way Illumina is being managed, Carl Icahn is engaged in a proxy contest with the DNA sequencing firm.
May 2, 2023
Hologic fiscal Q2 diagnostics revenue drops 53%; firm beats analyst estimates
Molecular Diagnostics revenue of $342.2 million fell 60% from $862.5 million in the prior year quarter, as COVID-19 testing demand plummeted.
May 1, 2023
Illumina NGS instrument software vulnerable to cybersecurity breach: FDA
Though it has received no reports that anyone has exploited a vulnerability in Illumina’s instrument software, the FDA said the possible impact on genomic data includes causing instruments to provide no results, incorrect results, or altered results.
May 1, 2023
OpGen prices $3.5M public stock offering
Gross proceeds of the offering, before the deduction of the placement agent’s fees and other expenses, are expected to be $3.5 million, the firm said.
May 2, 2023
Promis Diagnostics nabs FDA breakthrough device designation for bladder cancer test
The EarlyTect BCD test qualitatively detects an epigenetic biomarker, PENK methylation, associated with bladder cancer in the urine DNA of patients with hematuria.
April 28, 2023
ChromaCode, MedGenome collaborate on multiplexing platform availability in India and the Middle East
The technology has a simplified workflow with the aim of enabling laboratories worldwide to perform high-quality, cost-effective testing internally, the firms said in a statement.
April 28, 2023
Previous Page
Page 3 of 179
Next Page